CYTEA|BIO IS A PRECLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSING ON NOVEL LIGAND-DRIVEN IMMUNOTHERAPIES UTILIZING UNMODIFIED ALLOGENEIC CELLS AS EFFECTOR ENTITIES. THE COMPANY HAS DEVELOPED AND PATENTED A VERSATILE AND MODULAR THERAPEUTIC PLATFORM (PIN™ PLATFORM).
THE PLATFORM SOLVES THE PROBLEM OF PRE-ARMING NORMAL POTENT EFFECTOR CELLS WITHOUT CELL MODIFICATIONS THEREBY PROVIDING AN OPPORTUNITY TO CREATE MULTIPLE THERAPEUTIC PRODUCTS AND COMBINATIONS FROM WELL-UNDERSTOOD COMPONENTS.
ANY EFFECTOR CELL HAVING A NATURAL OR INDUCED CD16 RECEPTOR ON ITS SURFACE CAN BE USED WITHIN THE PLATFORM, INCLUDING NK CELLS OR OTHER IMMUNE CELLS.
ANY SINGLE OR MULTIPLE MONOCLONAL ANTIBODIES, OR OTHER FC-BASED LIGANDS CAN BE USED, ONCE ENGINEERED, TO PRE-ARM THE EFFECTOR CELLS BEFORE THERAPEUTIC ADMINISTRATION.
THE PLATFORM BRINGS TOGETHER SELECTIVE TARGETING LIGANDS WITH POTENT UNMODIFIED HUMAN CELLS, HARNESSING NATURAL IMMUNE PROCESSES BASED ON CONVENTIONAL MOLECULAR RECOGNITION, NORMAL CELL SIGNALLING AND EFFECTOR FUNCTION. NATURAL IMMUNE FUNCTIONS MAXIMIZE EFFICACY AND MINIMIZE SAFETY RISK.
Former Head of Manufacturing at Mesoblast (NASDAQ: MESO). Ex- Professor at UTMD Anderson Cancer Center. Led the Cell Therapy Laboratory at UTMD and designed its facility.
Former SVP Global Clinical Development at Merck KGaA with a strong track record of drug approval (Rebif, Mavenclad). Previously Head of Scientific Affairs and Investor Relations at Serono (listing NYSE).
CEO of the Grünenthal Group (€ 1,4B Sales, 4’700 employees in 2019). Previously Company President of AstraZeneca Japan and Germany. Managed brands in immuno-oncology.
Non-executive director. Formerly Ambassador to The People’s Republic of China, to Mongolia and the DPRK (2014-2019). Previously Ambassador to France and Monaco (2011-2014).
Highly experienced drug developer with a strong track record of drug approvals
Initiator & director of the Institute for Regenerative Medicines & Biotherapy (IRMB) at Montpellier, France.
80, AVENUE AUGUSTIN FLICHE,
34295 MONTPELLIER CEDEX 5,
FRANCE
AVENUE DES PLANCHES 20C,
1820 MONTREUX, SWITZERLAND
CYTEA|BIO IS A PIPELINE COMPANY OF MEDXCELL
VISIT MEDXCELL’S WEBSITE FOR MORE INFORMATION